THIO is a Telomere-by-Telomerase Targeting Agent in Development

For two decades now Telomerase was highly attractive, yet not extremely successfully pursued target in oncology. Chemical and structural modification, not shortening, of telomeres by telomerase, rather than inhibition of telomerase activity, is a new, recently introduced approach to specific cancer cell chromatin-targeted therapeutic approach. This new approach allows to completely eliminate the so-called “lag period in phenotypic responses” associated with the  application of “classic” telomerase inhibitor(s).  

Telomerase is present in >80% of human cancer cells and contributes significantly to proliferative abilities and immortality of cancer cells. It is either absent or shows very low activity in normal cells. THIO(6-thio-dG) is recognized by telomerase and incorporated into telomeres selectively in cancer cells. Once incorporated, it compromises telomere structure and function, leading to ‘uncapping’ of the chromosome ends resulting in rapid tumor cell death.

Only recently, in 2020, research by MAIA Biotech and the University of Texas Southwestern (UTSW), have identified never before observed immunogenic effects when low dose THIO is sequenced in advance of check-point inhibitors, the dominant standard of care immunotherapy.

MAIA Biotech plans to advance THIO to a Phase 1 clinical study in 2021.


 

Literature:

Mender et al., Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity, Cancer Cell (2020), https:// doi.org/10.1016/j.ccell.2020.05.020 https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30270-1

Mender et al. A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells. Oncoscience. 2015 Aug 22;2(8):693-5. https://www.ncbi.nlm.nih.gov/pubmed/26425659

Mender, et al. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2′-deoxyguanosine. Cancer Discovery. 2015 Jan;5(1):82-95. https://www.ncbi.nlm.nih.gov/pubmed/25516420

Mender et al. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 2018 Aug;20(8):826-837. https://www.ncbi.nlm.nih.gov/pubmed/30015158

Reyes-Uribe et al. Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene. 2018 Jul;37(30):4058-4072. https://www.ncbi.nlm.nih.gov/pubmed/29695835

Sengupta et al. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul;17(7):1504-1514. https://www.ncbi.nlm.nih.gov/pubmed/29654065

Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019 May;20(5):299-309. https://www.ncbi.nlm.nih.gov/pubmed/30760854

Zhang et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. https://www.ncbi.nlm.nih.gov/pubmed/29563139

Zhang G, Shay JW. Inducing rapid telomere irreparable damage in telomerase-expressing cancers. Oncotarget. 2018 Nov 9;9(88):35803-35804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254679/